Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Inflammasome Therapeutics

Inflammasome Therapeutics’ K8 Implant Cuts Lesion Growth by more than 50% in Geographic Atrophy after Three Months in Multi-Center Trial
From Inflammasome Therapeutics
Via Business Wire
Inflammasome Therapeutics Announces Topline 3-month Data from a Clinical Trial of its First-in-Class Dual Inflammasome Inhibitor, K8, in Geographic Atrophy, Demonstrating Rapid, Substantial and Significant Efficacy and Safety
From Inflammasome Therapeutics
Via Business Wire
Inflammasome Therapeutics Completes Enrollment in Study for First Oral Dual Inflammasome Inhibitor for Ophthalmic and Neuroinflammatory Diseases
From Inflammasome Therapeutics
Via Business Wire
Inflammasome Therapeutics Announces First Patient Dosed in Geographic Atrophy (GA) Clinical Trial
From Inflammasome Therapeutics
Via Business Wire
Inflammasome Therapeutics Announces First Patient Dosed in Phase I Diabetic Macular Edema Study of the Dual Inflammasome Inhibitor K8
From Inflammasome Therapeutics
Via Business Wire
Inflammasome Therapeutics to Enter Clinic with Treatment for Dry AMD
From Inflammasome Therapeutics
Via Business Wire
New Study Shows Multiple Inflammasomes Combine to Cause Lupus, Macular Degeneration and Other Neuroinflammatory Diseases Such as Alzheimer’s Disease and Multiple Sclerosis
From Inflammasome Therapeutics
Via Business Wire
Inflammasome Therapeutics’ CEO to Be Featured Speaker at Upcoming Virtual Summit on Inflammasomes
From Inflammasome Therapeutics
Via Business Wire
Inflammasome Therapeutics’ Kamuvudines Continue to Show Promise for Future Treatment – and Potentially a Cure – for Blindness in Seniors
From Inflammasome Therapeutics
Via Business Wire
Inflammasome Therapeutics to Develop Dual Sustained-Release HIV Prevention and Birth Control Implant
From Inflammasome Therapeutics
Via Business Wire
Inflammasome Therapeutics’ Kamuvudines May Be Answer to Preventing Blindness in Aging Population
From Inflammasome Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.